- Report
- October 2023
- 177 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- October 2023
- 88 Pages
India
From €3355EUR$3,500USD£2,804GBP
- Report
- December 2022
- 112 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- March 2024
- 200 Pages
Global
From €3978EUR$4,150USD£3,324GBP
- Report
- August 2022
- 119 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- September 2023
- 160 Pages
Global
From €3450EUR$3,599USD£2,883GBP
- Report
- January 2024
- 168 Pages
Global
€4789EUR$4,995USD£4,001GBP
- Report
- May 2023
- 99 Pages
Global
From €3500EUR$3,911USD£3,027GBP
- Report
- May 2023
- 92 Pages
Middle East, Africa, Global Middle East, Africa, Global
From €3500EUR$3,911USD£3,027GBP
Blood cancer, also known as hematological cancer, is a type of cancer that affects the blood, bone marrow, and lymphatic system. It is a broad term that encompasses a variety of cancers, including leukemia, lymphoma, and myeloma. These cancers are caused by the abnormal production of blood cells, which can lead to anemia, infections, and other serious health problems. Treatment for blood cancer typically involves chemotherapy, radiation, and/or stem cell transplants.
The blood cancer market is a rapidly growing segment of the hematology market. It is driven by the increasing prevalence of blood cancer, advances in treatment options, and the availability of new drugs. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed.
Some of the major companies in the blood cancer market include Novartis, Celgene, Amgen, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and commercialization of drugs for the treatment of blood cancer. Show Less Read more